Vistagen Therapeutics Stock (NASDAQ: VTGN)

Vistagen Therapeutics Stock (NASDAQ:VTGN), Trade Ideas

Vistagen Therapeutics

VistaGen Therapeutics

Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. The company's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. The portfolio of the company includes PH94B, a novel neuroactive nasal spray; PH10, an odorless, fast-acting synthetic neurosteroid and AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR) which is the Company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy.

Analyst Color

Biotech

Equities

News

Penny Stocks

Health Care

Price Target

Initiation

Markets

Analyst Ratings

Movers

Trading Ideas

General

VTGN

William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety disorder (SAD) and other 

Undervalued VistaGen Therapeutics, Analyst Highlights Potential In Anxiety Treatment

Analysts at Stifel recently initiated coverage on Vistagen Therapeutics Inc (NASDAQ: VTGN), emphasizing the potential of its lead asset, fasedienol, in clinical development for social anxiety disorder (SAD).

Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst

Small Cap

Pre-Market Outlook

AGBA

AMAM

ATHX

AVGR

CNET

JAGX

NCNA

NTCT

NVVE

PCSA

RANI

SPRC

WISA

XTLB

XXII

YGMZ

Gainers


	SciSparc Ltd.  (NASDAQ: SPRC) shares surged 79.5% to $5.08 in pre-market trading after falling around 7% on Monday. SciSparc recently regained compliance with the Nasdaq Minimum Bid Price Notification.


Why Vistagen Therapeutics Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

VistaGen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics Inc

<p>The <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38331688/peter-schiff-slams-bitcoin-for-not-being-the-safe-haven-asset-its-promoted-to-be-af">recent market dip</a> in <strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) saw a significant increase in the holdings of large investors, commonly referred to as &#8220;whales,&#8221; who collectively added over $1.2 billion worth of BTC to their portfolios.</p>
<p><strong>What Happened</strong>: On Friday, as the price of Bitcoin dropped below $60,000, large investors increased their holdings by 19,760 BTC, equivalent to $1.2 billion, according to a report by <a href="https://www.coindesk.com/markets/2024/04/19/bitcoin-whales-bought-12b-btc-amid-the-price-dip-fueling-the-quick-rebound/">CoinDesk</a>, citing data from IntoTheBlock.</p>
<p>This move is seen as a significant shift in the behavior of these influential market players.</p>
<p>"Bitcoin whales may have finally started buying the dip," said IntoTheBlock.</p>
<p>These large investors, who control substantial amounts of the digital asset, are often considered to be well-informed and their actions can have a considerable impact on the market.</p>
<p><em>See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38321897/dogecoin-shiba-inu-and-who-else-how-meme-coins-have-evolved-since-the-last-bitcoin-halving?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Dogecoin, Shiba Inu And Who Else? How Meme Coins Have Evolved Since The Last Bitcoin Halving</a></em></p>
<p>Their recent purchases may have contributed to Bitcoin&#8217;s rapid recovery from its overnight low of $59,600 to around $65,000. The cryptocurrency is currently trading at approximately $64,000, marking a 1% increase over the past 24 hours.</p>
<p>"Historically, accumulations by these addresses have often preceded rises in Bitcoin&#8217;s price."</p>
<p>Bitcoin, the largest cryptocurrency by market capitalization, has been experiencing a period of consolidation following record-breaking prices last month.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">Bitcoin whales may have finally started buying the dip&#x1f447;<br /><br />Yesterday, the biggest Bitcoin holders, holding over 0.1% of the total supply, collectively added 19,760 Bitcoins to their holdings at an average price of $62.5k. Historically, accumulations by these addresses have often… <a href="https://t.co/c8K5uhkna4">pic.twitter.com/c8K5uhkna4</a></p>
<p>&mdash; IntoTheBlock (@intotheblock) <a href="https://twitter.com/intotheblock/status/1781263617528045852?ref_src=twsrc%5Etfw">April 19, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Why It Matters</strong>: The recent behavior of Bitcoin whales is significant as it indicates a shift in market sentiment. This comes at a time when a new report has shed light on the <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38317307/bitcoin-halving-will-institutions-and-smart-money-upend-past-price-rallies">role of institutions</a> and &#8220;smart money&#8221; in influencing Bitcoin&#8217;s price action.</p>
<p>Despite concerns about potential price volatility, Bitcoin has <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38340794/bitcoin-in-the-danger-zone-is-a-20-price-crash-imminent">held strong</a> following the fourth halving event, which saw miner rewards reduced from 6.25 BTC to 3.125 BTC.</p>
<p><strong>Price Action:</strong> At the time of writing, Bitcoin was hovering at $63,694, reflecting a 0.1% increase in the last hour and a 5.9% increase in the last 24 hours, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro</a>.</p>
<p><em>Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38306270/dogecoin-could-make-elon-musks-fate-loves-irony-comment-come-true-if-it-flips-ethereums-ma?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Dogecoin Could Make Elon Musk&#8217;s &#8216;Fate Loves Irony&#8217; Comment Come True If It Flips Ethereum&#8217;s Market Cap</a></em></p>
<p><strong><em>Disclaimer:</em></strong><em> This content was partially produced with the help of </em><a href="https://www.benzinga.com/author/benzinga-neuro"><em>Benzinga Neuro</em></a><em> and was reviewed and published by Benzinga editors.</em></p>
<p><em>Image generated using Dall-E</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Whales Scoop Up $1.2B Worth Of BTC During Market Dip: Is Potential Rally For King Crypto On The Cards?

<p>The New York Attorney General <strong>Letitia James</strong>' office has moved to invalidate the $175 million bond secured by former President <strong>Donald Trump</strong> to delay payment of a larger monetary damage award in his <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37203878/peter-schiffs-theory-on-trump-ny-civil-fraud-case-ruling-attempt-to-scare-other-bus">civil fraud </a>case.</p>
<p><strong>What Happened</strong>: The New York attorney general&#8217;s office has filed a request with a judge to nullify the <a href="https://www.benzinga.com/news/24/04/38037983/trump-clears-175m-bond-in-new-york-fraud-case-avoiding-potential-asset-seizures">$175 million bond</a> that Trump secured, arguing that the former president and his co-defendants failed to prove the surety used to obtain the bond has the money to back it, <a href="https://thehill.com/regulation/court-battles/4606053-ny-ag-trump-civil-fraud-judge-declare-175m-bond-without-effect/">The Hill</a> reported. </p>
<p>The bond was secured by the California-based <strong>Knight Specialty Insurance Company</strong>. The state lawyers contended that Knight is a &#8220;small insurer that is not authorized to write business in New York&#8221; and had &#8220;never before written a surety bond in New York&#8221; until Trump.</p>
<p>The company&#8217;s total policyholder surplus is just $138 million, and under New York state law, companies like Knight can&#8217;t expose themselves to liabilities greater than 10% of their surplus.</p>
<p><em>See Also: <a href="https://www.benzinga.com/news/24/04/38305609/teary-biden-slams-trump-for-remarks-on-service-members-who-the-hell-does-he-think-he-is?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Teary Biden Slams Trump For Remarks On Service Members: &#8216;Who The Hell Does He Think He Is?&#8217;</a></em></p>
<p><strong>Why It Matters:</strong> The civil fraud case against Trump and his organization was initiated by the New York Attorney General. The case alleges that Trump and his organization <a href="https://www.benzinga.com/news/24/04/38103939/letitia-james-raises-questions-legitimacy-of-trumps-175m-bond-ex-presidents-attorney-says-another-wi">manipulated the value of assets</a> to obtain loans and tax benefits.</p>
<p>The judge is expected to address the issues raised by the attorney general&#8217;s office in a hearing on Monday, which will run parallel to the opening statements in Trump&#8217;s New York criminal trial.</p>
<p>These developments come amid a series of dramatic events surrounding Trump&#8217;s legal proceedings. On Friday, a <a href="https://www.benzinga.com/general/politics/24/04/38342704/protester-sets-self-on-fire-outside-trump-hush-money-trial-jury-selection-concludes-before-monda">protester set themselves on fire</a> outside the courtroom where Trump&#8217;s hush money trial was being held. This incident briefly interrupted the jury selection process.</p>
<p>Donald Trump is currently <a href="https://www.benzinga.com/news/23/03/31392130/trump-camp-slams-stormy-daniels-case-as-witch-hunt-by-radical-left-democrat-prosecutor" target="_blank" rel="noreferrer noopener">dealing with legal challenges</a> on both federal and state levels, across different places like New York City, Washington, Atlanta, Florida, and Georgia. Despite the allegations, he continues to assert his innocence, describing the cases as a &#8220;witch hunt.&#8221;</p>
<p><a href="https://www.realclearpolitics.com/" target="_blank" rel="noreferrer noopener">According</a> to Real Clear Politics, at the national level, Trump held 44.6% support among voters, While Biden trailed with 44.2% support.</p>
<p><em>Read Next: <a href="https://www.benzinga.com/news/24/04/38305694/former-trump-attorney-says-very-unusual-to-have-lawyers-on-the-jury-they-can-be-a-very-strong-voice?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Former Trump Attorney Says &#8216;Very Unusual&#8217; To Have Lawyers On The Jury: &#8216;They Can Be A Very Strong Voice&#8217;</a></em></p>
<p><em>Photo courtesy: Shutterstock</em></p>


Politics

NY AG Letitia James Seeks To Void Trump's $175M Bond In Civil Fraud Case

<p>Renowned crypto skeptic <strong>Peter Schiff</strong> took to <strong>X</strong>, formerly <strong>Twitter</strong>, to mock "Bitcoiners" after the <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38345043/bitcoin-shrugs-off-fourth-halving-miner-rewards-halved-price-holds-strong">recent halving event</a>, suggesting that the "hodlers" will soon experience a halving of their net worth.</p>
<p><strong>What Happened:</strong> Schiff sarcastically congratulated Bitcoin holders and asked if they were "throwing parties" to celebrate the halving event.</p>
<p>"Congratulations Bitcoiners on the Halving. Are you guys commemorating this occasion by throwing parties tonight? I haven&#8217;t been invited to any."</p>
<p>Bitcoin halving has taken place, with the 840,000th block having been mined. The mining reward has now been reduced to 3.125 BTC per block, compared to 6.25 BTC previously.</p>
<p>Bitcoin halving takes place every 210,000 blocks, and there are 21 million blocks in total. It is expected that this limit will be reached in 2040.</p>
<p><em>See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38299089/trump-related-maga-memecoin-onboards-roger-stone-as-partner?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump-Related MAGA Memecoin Onboards Roger Stone As Partner</a></em></p>
<p>While the halving event has reduced rewards for miners, Schiff mocked those holding the King Crypto.</p>
<p>"I think halving is an appropriate name for what&#8217;s happening as soon Bitcoin HODLers will experience a halving of their net worths."</p>
<p><figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="581" height="259" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19213002/Peter-Schiff-1.jpg" alt="" class="wp-image-300797" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19213002/Peter-Schiff-1.jpg 581w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19213002/Peter-Schiff-1-300x134.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></figure></p>
<p><strong>Why It Matters:</strong> The post comes after the completion of the fourth Bitcoin halving event, which occurred after the 840,000th block was mined. This event, which happens approximately every four years, is <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38341469/happy-bitcoin-halving-day-what-experts-predict-happens-next">designed to manage scarcity</a> and regulate the inflationary supply of Bitcoin.</p>
<p>This process effectively slows down the rate at which new Bitcoin is created. The last three halvings occurred in 2012, 2016, and 2020, leading to significant drops in mining rewards over time.</p>
<p>Some analysts have warned of <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38340794/bitcoin-in-the-danger-zone-is-a-20-price-crash-imminent">potential price volatility</a> following the halving. Pseudonymous cryptocurrency analyst Rekt Capital, for example, cautioned that the imminent Bitcoin halving may lead to price volatility.</p>
<p><strong>Price Action:</strong> At the time of writing, Bitcoin was hovering at $63,600, down 0.1% in the last hour, and up 2.4% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.</p>
<p><em>Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38284502/dogecoin-killer-shiba-inu-sees-significant-increase-in-token-burn-rate-as-price-recovers-i?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Dogecoin Killer&#8217; Shiba Inu Sees Significant Increase In Token Burn Rate As Price Recovers</a></em></p>
<p><strong><em>Disclaimer:</em></strong><em>&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.</em></p>
<p>Image: Pete Linforth from Pixabay</p>


Tech

Peter Schiff Mocks 'Bitcoiners' After Halving Event, Asks If They're 'Throwing Parties:' 'Hodlers Will Experience A Halving Of Their Net Worths'

<p>Bitcoin experienced a 1.5% increase over the last 24 hours following the successful completion of the fourth <strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/money/what-is-bitcoin-halving">halving event</a>, signifying a notable reduction in miner rewards. The event, which occurs every 210,000 blocks, has seen the reward for mining a block drop from 6.25 BTC to 3.125 BTC.</p>
<p><strong>What Happened</strong>: The fourth Bitcoin halving event, a programmed process in the Bitcoin protocol, has taken place after the 840,000th block <a href="https://bitcoinhalving.club/">was</a> mined. This event, which occurs approximately every four years, is designed to manage scarcity and regulate the inflationary supply of Bitcoin.</p>
<p>As a result of the halving, Bitcoin miners will now receive 3.125 BTC per mined block, down from the previous 6.25 BTC. This process effectively slows down the rate at which new Bitcoin is created. The last three halvings occurred in 2012, 2016, and 2020, leading to significant drops in mining rewards over time.</p>
<p><em>See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38284502/dogecoin-killer-shiba-inu-sees-significant-increase-in-token-burn-rate-as-price-recovers-i?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Dogecoin Killer&#8217; Shiba Inu Sees Significant Increase In Token Burn Rate, As Price Recovers — Is A Turnaround In The Making?</a></em></p>
<p>Despite short-term predictions of price volatility within the crypto community, there remains optimism about the long-term potential of Bitcoin&#8217;s price. Billionaire investor <strong>Tim Draper</strong> believes that the halving is going to help push Bitcoin's price up to "$250,000 or more," a forecast he has consistently proclaimed, particularly in 2022.</p>
<p>&#8220;The Bitcoin halving is a pivotal event that historically signals a shift in the market, usually initiating a bullish trend over the following months. As we approached the fourth halving, the anticipation built, suggesting a continued—if slightly more subdued—upward trajectory,&#8221; M2 CEO Stefan Kimmel <a href="https://cointelegraph.com/news/bitcoin-halving-2024-completion-confirmed">told</a> Cointelegraph.</p>
<p><strong>Why It Matters</strong>: Cryptocurrency <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38342981/bitcoin-ethereum-dogecoin-pick-up-steam-the-pre-halving-week-in-retrospect">markets surged on Friday</a>, with a 47.5% spike in total crypto liquidations reaching $258.7 million and a more than double increase in total exchange inflows, as investors eagerly awaited the <a href="https://www.benzinga.com/topic/bitcoin-halving" target="_blank" rel="noreferrer noopener">Bitcoin Halving</a>.</p>
<p>The global cryptocurrency market cap now stands at 2.35 trillion, up 4.7% in the past 24 hours. In the same period, 84,226 traders were liquidated, with total liquidations amounting to $257.93 million, on late Friday. </p>
<p><strong>Price Action</strong>: At the time of writing BTC was trading at $63,914, gaining 0.7% in minutes after halving, according to <a href="http://pro.benzinga.com">Benzinga Pro.</a></p>
<p><em>Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38293168/macro-guru-raoul-pal-says-80-of-his-crypto-investment-is-in-this-ethereum-rival-and-i-have?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Macro Guru Raoul Pal Says 80% Of His Crypto Investment Is In This Ethereum Rival: &#8216;And I Have 1% In Stupid S&#x2A;&#x2A;t Like Dogwifhat, Dogecoin And Bonk&#8217;</a></em></p>
<p><em>Photo courtesy: Shutterstock</em></p>


Bitcoin Shrugs Off Fourth Halving: Miner Rewards Halved, Price Holds Strong

SMFL

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

<p>As 4/20 is upons us, <a href="https://www.benzinga.com/topic/weedmaps">Weedmaps </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>) has provided valuable insights to forecast a significant sales boost for the industry and a widespread celebration of marijuana. The data, derived from big data analysis of user activities on the platform, indicates that the previous year&#8217;s 4/20 was highly successful, with Weedmaps experiencing a twofold increase in normal operations.</p>
<h2 class="wp-block-heading">Big Data, Big Deals</h2>
<p>Weedmaps pointed out that consumers are prioritizing value, as the platform registered a 200% surge in orders that redeem deals through the platform during 4/20 week of 2023 compared to 2022.&nbsp;</p>
<p>Furthermore, the platform has observed a rising trend in usage, with deal claims increasing by 100% over 2022. This uptick is likely motivated by price reductions, as the costs for flowers, vape pens, and edibles have continued to decrease for the second consecutive year, showing declines of 15%, 14%, and 17% when compared to 2021.</p>
<p>Weemaps also shared that consumers will probably be expending even more in goods than years before, since the average order value surged to $96.22 in 2023, a 14% increase compared to an average Thursday in April of 2023. This is despite deflation.</p>
<p>Additionally, the quantity of orders expanded by an average of 25% in terms of items per basket on 4/20 of last year, in comparison to 2022.</p>
<h2 class="wp-block-heading">Category Insights</h2>
<ul>
<li>During the 4/20 retail week of 2023, vape pens witnessed a 29% growth over 2022, and an impressive 126% increase compared to 2020, with the largest demographic being Gen Z (31%).</li>
</ul>
<ul>
<li>Edibles are predominantly favored by consumers aged 50 and above, accounting for nearly half of all edible sales. The edibles category saw a 36% rise in orders during the 4/20 week of 2023 compared to the previous year.</li>
</ul>
<ul>
<li>Cannabis flower remains the top choice across all age groups, with nearly half of all orders on 4/20 in 2023 falling into this category. Remarkably, sales of flowers through Weedmaps surged by 47% on 4/20 compared to the prior year, and this growth expanded to 202% when compared to 4/20 in 2020.</li>
</ul>


Cannabis

MAPS

Unparalleled 4/20: Weedmaps Unveils Consumer Trends Ahead Of Cannabis Industry's Biggest Holiday

<p>As you may have heard, cannabis consumption among older folks is on the rise. More specifically, seniors are one of the fastest-growing groups of <a href="https://www.benzinga.com/cannabis">cannabis users in the U.S. </a></p>
<p>As it turns out, many older adults have been consuming weed for decades and new ones are joining in on the fun. Cannabis consumption among our parents and grandparents has quadrupled in the past eight years.</p>
<p>Study after study suggests that older adults are using cannabis to remedy an array of conditions such as sleep issues, pain,&nbsp;inflammation and to activate their appetites. </p>
<p>But most consume because they still enjoy getting high.</p>
<p>"Sure, I sleep better with cannabis and topical creams alleviate my knee pain, but that's all new. I've been smoking pot for the past four decades and I see no reason to stop getting high," said Cynthia P who recently retired as an ER nurse in Ohio where recreational marijuana <a href="https://www.benzinga.com/markets/cannabis/23/11/35664155/ohio-legalizes-cannabis-and-overwhelmingly-approves-abortion-rights">became legal</a> last November.</p>
<p>Scientists and researchers are wisely becoming interested in this Baby Boomer demographic of 77 million, many of whom are healthy, economically stable and have no plans of checking out anytime soon, so they say.</p>
<p>One particular<a href="https://www.frontiersin.org/articles/10.3389/fnagi.2022.804890/full" target="_blank" rel="noreferrer noopener">&nbsp;study</a>,&nbsp;that examined marijuana use in adults aged&nbsp;60 to 88 found that&nbsp;whole-plant cannabis did&nbsp;not harm&nbsp;cognition but rather the opposite.&nbsp;Older cannabis users, relative to non-users, had&nbsp;significantly greater neuronal communication between the cerebellum and hippocampus.</p>
<p><strong>Why?</strong> Age-related changes in the&nbsp;<a href="https://www.benzinga.com/markets/cannabis/22/07/28272841/the-endocannabinoid-system-101-the-basics-made-easy" target="_blank" rel="noreferrer noopener">endocannabinoid system</a>&nbsp;(ECS) include a decrease in the number of cannabinoid receptors throughout the brain.&nbsp;The ECS,&nbsp;a significant aspect of our human physiology that&nbsp;helps maintain homeostasis,&nbsp;is a complex cell-signaling system in the brain and body that interacts with just about all of our&nbsp;other body systems.&nbsp;</p>
<p><strong>Which means? </strong>During normal aging, the decline in cannabinoid receptors correlates with increased levels of inflammation in these brain regions causing a loss of neurons in the hippocampus, which is critical for learning and&nbsp;memory.&nbsp;This, in short, explains age-related memory impairment.&nbsp;&nbsp;</p>
<p>"Oh, I believe that," Cynthia told Benzinga. "While I never consumed for a full shift before going to work, I'm convinced that marijuana has helped keep me and my mind sharp as I aged. I'm not saying it's for everyone, but for people of my generation there's nothing better."</p>
<p><em>Now Read: <a href="https://www.benzinga.com/markets/cannabis/24/04/38341776/hemp-space-grew-3x-the-rate-of-cannabis-where-did-marijuana-get-it-wrong">Hemp Space Grew 3X The Rate Of Cannabis, Where Did Marijuana Get It Wrong?</a></em></p>
<p><em>Photo: Shutterstock</em></p>


Exclusives

It's 4/20, Do You Know Where Your Parents Are?

<p>The Detroit Lions finished with one of their best records in years for the 2023 season, which means they will have a lower pick in the<a href="https://www.benzinga.com/nfldraft/"> 2024 NFL Draft.</a></p>
<p>Would General Manager<strong> Brad Holmes</strong> consider trading out of the first round with the 2024 NFL Draft taking place in Detroit?</p>
<p><strong>What Happened: </strong>Detroit Lions fans might not like the answer given by Holmes to the media on scenarios that could see the Lions trade their 29<sup>th</sup> overall first-round pick and move back in the <a href="https://www.benzinga.com/nfldraft/detroit-live-events/">2024 NFL Draft.</a></p>
<p>Holmes was asked about a scenario of trading out of the first round and didn't hesitate to say he will do what is best for the franchise.</p>
<p>"We have to do the right thing for the organization," Holmes said, as <a href="https://www.detroitlions.com/news/holmes-prepared-to-apologize-to-fans-if-lions-trade-out-of-first-round">reported </a>by Lions writer Mike O'Hara.</p>
<p>Holmes said while he would consider trading out of the first round, it's important to note that, with the draft taking place in Detroit, there might be a greater chance of upsetting the fans if he makes such a move.</p>
<p>A trade out of the first round could mean that any Lions fans in attendance Thursday will have spent all day downtown to watch other teams take their players in the draft.</p>
<p>Holmes said he would send out a "PSA and apologize" if he trades out of the first round.</p>
<p>"Hopefully, our fans will forgive us. We won't expect immediate forgiveness right then and there, but hopefully when the season starts."</p>
<p>Detroit was announced as the host city for the NFL Draft back in 2022.</p>
<p>"Another opportunity for our franchise and our city and just for the world to kind of migrate to downtown Detroit," Holmes said earlier this week.</p>
<p><em>Related Link: <a href="https://www.benzinga.com/general/sports-betting/24/04/38318190/michigan-wolverines-will-have-6-high-demand-players-in-2024-nfl-draft-will-history-repeat-">Michigan Wolverines Will Have 6 High-Demand Players In 2024 NFL Draft: Will History Repeat Itself?</a></em></p>
<p><strong>Why It's Important:</strong> Holmes is no stranger to trading in the NFL Draft. Since joining as the Lions GM in 2021, Holmes has taken part in several drafts for the team and is known for dealmaking.</p>
<p>This includes the 2023 NFL Draft, which saw the Lions trade their sixth overall pick, acquired from the Los Angeles Rams in the <strong>Matthew Stafford</strong> trade. The Lions traded the sixth pick to the Arizona Cardinals and received back the 12<sup>th</sup>, 34<sup>th</sup> and 168<sup>th</sup> overall picks.</p>
<p>Lions fans will remember the 2023 Draft saw several impact players taken including running back <strong>Jahymyr Gibbs </strong>with the 12<sup>th</sup> pick and tight end<strong> Sam LaPorta </strong>with the 34<sup>th</sup> pick. Both rookies played in the 2023 NFL season and were among the top first-year players, finishing third and fourth, respectively, in NFC offensive rookie of the year voting.</p>
<p>The 12-5 record and appearance in the NFC Championship game gives the Lions the 29<sup>th</sup> overall pick, one of their lowest earned in years.</p>
<p>The Lions also have the 61<sup>st</sup> overall pick and 73<sup>rd</sup>, but have only those three picks in the first four rounds, with no fourth-round pick this year. This could prompt Holmes to be open to trades to pick up additional picks. The Lions also have a fifth-round pick, two sixth-round picks and a seventh-round pick, for seven overall picks.</p>
<p>In the 2023 NFL Draft, the Lions had eight picks, including two first-round picks and two second-round picks.</p>
<p>The Lions have had a first round pick in every season since 1994, with 1993 being the last year they didn't select a player in the first round.</p>
<p>The Lions&#8217; top needs by position include cornerback, offensive line and wide receiver. The Lions last took a wide receiver in the first round of 2022 (<strong>Jameson Williams</strong>) and a cornerback in the first round of 2020 (<strong>Jeff Okudah</strong>). For the offensive line, the Lions last took a guard or center in the first round in 2018 with <strong>Frank Ragnow,</strong> and last took an offensive tackle in the first round in 2021 with <strong>Penei Sewell.</strong> Of these four players, three are still with the Lions.</p>
<p>Join Benzinga's live draft reaction show Thursday, April 25 to hear our instant thought on who the Lions take 29<sup>th</sup> overall or our reaction to the Lions trading out of the first round.</p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534; LIVE NFL Draft Watch Party: Benzinga&#039;s Expert Analysis &amp; Reactions!" width="500" height="281" src="https://www.youtube.com/embed/XMBqIWZb7h0?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p><em>Photo via Shutterstock. </em></p>


Sports

Detroit Lions Have First-Round Pick Every Year Since 1994: Would They Really Trade Out With Draft In Motor City?

<p>&quot;We are disappointed to announce the wind-down of our Phase 2 NASH trial, which we attribute entirely to resource constraints,&quot; said John Brancaccio, Executive Chairman of Hepion. &quot;The Company remains committed to its strategic alternative efforts previously announced in December 2023. Given the number of enrolled NASH patients to date and the low probability of generating relevant efficacy data to support a registrational trial with our current cash resources, we have opted to wind down the program and assure that patients are transitioned out of the trial in a safe and compliant manner. There were no safety concerns observed for rencofilstat in the ASCEND-NASH trial.&quot;</p>


HEPA

Hepion Pharmaceuticals Says Given The Number Of Enrolled NASH Patients To Date And The Low Probability Of Generating Relevant Efficacy Data To Support A Registrational Trial With Our Current Cash Resources, We Have Opted To Wind Down The Program And Assure That Patients Are Transitioned Out Of The Trial In A Safe And Compliant Manner"

Hepion Pharmaceuticals Shares Resumed Trading

<p>Sen.<strong> Elizabeth Warren</strong> (D-Mass.) voiced her support for a Department of Justice antitrust case against leading technology company <strong>Apple Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), which was <a href="https://www.benzinga.com/news/24/03/37905532/apple-slams-dangerous-doj-lawsuit-tim-cooks-iphone-suggestion-returns-to-haunt-and-potential-google">announced last month.</a></p>
<p>In comments shared on social media, Warren took aim at the smartphone market segment of Apple.</p>
<p><strong>What Happened:</strong> Apple is one of the largest smartphone companies in the world and in 2023 had seven of the top 10 selling smartphones globally <a href="https://www.benzinga.com/news/24/02/37245799/apple-dominates-2023-smartphone-list-with-7-of-top-10-models-why-its-important-for-iphone-growth">according to a report.</a></p>
<p>According to Warren, Apple has a monopoly in the smartphone market and one of the company's key features could be ruining friendships and relationships.</p>
<p>"Green texts on iPhones, they're ruining relationships," Warren <a href="https://twitter.com/SenWarren/status/1781086997014040759">said </a>in a video posted on X.</p>
<p>The green texts refer to the texts that come from non-Apple phones in green bubbles versus the blue bubbles displayed by iPhone users.</p>
<p>"Non iPhone users everywhere are being excluded from group texts."</p>
<p>Warren said that this means some non-Apple smartphone users are not being included in chats about vacation plans, group chats or chats with other sports fans.</p>
<p>"And who's to blame here? Apple."</p>
<p>Warren said that the green vs. blue bubble text icons are just one example of the dirty tactics used by Apple to "keep a stranglehold on the smartphone market."</p>
<p>"Apple has used its monopoly on the smartphone to lock Americans into services and amass billions of dollars in profits."</p>
<p>Warren mentioned that apps that would let Google users use iMessage and get blue texts were <a href="https://www.benzinga.com/news/23/12/36165068/apple-pulls-plug-on-imessage-for-android-app-beeper-mini-its-back-to-green-bubbles-now-for-android-u">blocked by Apple.</a></p>
<p>"It's time to break up Apple's monopoly now."</p>
<p><em>Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37876155/apple-doj-lawsuit-could-challenge-core-business-model-leading-analyst-predicts-what">Apple DOJ Lawsuit Could Challenge &#8216;Core Business Model&#8217;: Leading Analyst Predicts What&#8217;s Next For Tech Giant</a></em></p>
<p><strong>Why It's Important</strong>: The video shared by Warren was Community Noted on X, with readers providing more context.</p>
<p>"As of Jan 2024, iPhone has a 57% market share, to Android 42% in North America. A monopoly is exclusive control, or no close substitutes," the note reads.</p>
<p>In March, the Department of Justice filed an antitrust suit against Apple, which includes allegations that the company restricts access to iPhone hardware and software features.</p>
<p>A <a href="https://9to5mac.com/2024/04/19/elizabeth-warren-on-green-texts/">report </a>from 9to5Mac indicates that the antitrust lawsuit now encompasses claims from non-iPhone users who feel socially stigmatized and excluded in chats with iPhone users. This issue stems from the ongoing<a href="https://www.benzinga.com/news/23/09/34818276/get-the-message-google-roasts-apple-with-new-mocking-ipager-add-to-end-green-vs-blue-text-bubbles-wa"> blue vs. green bubble text debate.</a></p>
<p><strong>AAPL Price Action</strong>: Apple shares closed at $165.00 on Friday, versus a 52-week trading range of $162.80 to $199.62.</p>
<p><em>Read Next:<a href="https://www.benzinga.com/general/politics/24/04/38305131/elizabeth-warren-says-trump-had-only-2-accomplishments-as-president-huge-difference-between-bide"> Elizabeth Warren Says Trump Had Only 2 Accomplishments As President: &#8216;Huge Difference Between&#8217; Biden, Trump</a></em></p>
<p><em>Photo: Shutterstock</em></p>


Legal

AAPL

Elizabeth Warren Attacks Apple Smartphone 'Monopoly': 'Green Texts On iPhones, They're Ruining Relationships'

Trading Halt: Halt status updated at 4:55:00 PM ET: Quotation Resumption: News and Resumption Times

Management

AFJK

On April 15, Aimei Health Technology's Juan Fernandez Pascual Tendered His Resignation As CEO, Secretary And A Director; Co Appointed Junheng Xie As CEO, Secretary And A Director

Global

Honda Exec Says Company To Invest 4.2B Reais In Brazil Plant, Focusing On Hybrid-Flex Vehicles

COSM

Cosmos Health Received Nasdaq Notice On Late Filing Of Its Form 10-K; On April 17 Received Notification Letter Stating Co Is No Longer In Compliance With Nasdaq Listing Rule 5250(c)(1); Intends To Resolve Deficiency And Regain Compliance With Nasdaq Listing Rules

BTOG

On Feb 19, Bit Origin Ltd Terminated Employment Of Its CFO, Xia Wang; On April 10, Lucas Wang Resigned As CEO And Chairman Of Board; Current COO, Has Been Appointed CEO, Chairman Of Board And A Director Of Co; Co To Conduct A Search To Replace Xia Wang As Company's CFO

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>ServiceNow</strong>.</p>
<p>Looking at options history for ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) we detected 56 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations and 64% with bearish.</p>
<p>From the overall spotted trades, 25 are puts, for a total amount of $1,473,153 and 31, calls, for a total amount of $2,469,435.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $300.0 to $1040.0 for ServiceNow over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for ServiceNow's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ServiceNow's whale trades within a strike price range from $300.0 to $1040.0 in the last 30 days. </p>
<h3>ServiceNow Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713559550_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$108.8</td>
<td>$106.7</td>
<td>$108.8</td>
<td>$700.00</td>
<td>$598.4K</td>
<td style="text-align: right;">142</td>
<td style="text-align: right;">56</td>
</tr>
<tr>
<td>NOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$37.0</td>
<td>$31.7</td>
<td>$36.5</td>
<td>$500.00</td>
<td>$310.2K</td>
<td style="text-align: right;">35</td>
<td style="text-align: right;">85</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/10/24</td>
<td>$39.1</td>
<td>$36.7</td>
<td>$39.1</td>
<td>$700.00</td>
<td>$293.2K</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">75</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$32.8</td>
<td>$32.1</td>
<td>$32.1</td>
<td>$720.00</td>
<td>$227.9K</td>
<td style="text-align: right;">75</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$33.0</td>
<td>$31.9</td>
<td>$33.0</td>
<td>$800.00</td>
<td>$132.0K</td>
<td style="text-align: right;">131</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About ServiceNow</h3>
<p>ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.</p>
<h3>Current Position of ServiceNow</h3>
<ul>
<li>Trading volume stands at 1,536,830, with NOW's price down by -2.39%, positioned at $713.91.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 5 days.</li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for ServiceNow, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

This Is What Whales Are Betting On ServiceNow

<p>Financial giants have made a conspicuous bearish move on AstraZeneca. Our analysis of options history for AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) revealed 12 unusual trades.</p>
<p>Delving into the details, we found 16% of traders were bullish, while 83% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $90,336, and 9 were calls, valued at $981,928.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $66.0 and $77.5 for AstraZeneca, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for AstraZeneca's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AstraZeneca's whale activity within a strike price range from $66.0 to $77.5 in the last 30 days. </p>
<h3>AstraZeneca Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713559545_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.06</td>
<td>$0.9</td>
<td>$0.9</td>
<td>$67.50</td>
<td>$594.6K</td>
<td>14.1K</td>
<td>8.2K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.65</td>
<td>$1.54</td>
<td>$1.55</td>
<td>$67.00</td>
<td>$69.4K</td>
<td>2.5K</td>
<td>2.3K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.52</td>
<td>$1.51</td>
<td>$1.51</td>
<td>$67.00</td>
<td>$67.6K</td>
<td>2.5K</td>
<td>1.0K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$1.49</td>
<td>$1.25</td>
<td>$1.49</td>
<td>$67.00</td>
<td>$66.7K</td>
<td>2.5K</td>
<td>24</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.57</td>
<td>$1.48</td>
<td>$1.49</td>
<td>$67.00</td>
<td>$49.6K</td>
<td>2.5K</td>
<td>920</td>
</tr>
</tbody>
</table>
</p>
<h3>About AstraZeneca</h3>
<p>A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.</p>
<p>Following our analysis of the options activities associated with AstraZeneca, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is AstraZeneca Standing Right Now?</h3>
<ul>
<li>With a trading volume of 4,720,283, the price of AZN is up by 0.28%, reaching $68.55.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 6 days from now.</li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AstraZeneca options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Looking At AstraZeneca's Recent Unusual Options Activity

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Astera Labs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALAB, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 9 options trades for <strong>Astera Labs</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 44% bullish and 55%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $55,500, and 8, calls, for a total amount of $413,781.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $35.0 to $100.0 for Astera Labs during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Astera Labs's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Astera Labs's whale trades within a strike price range from $35.0 to $100.0 in the last 30 days. </p>
<h3>Astera Labs Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713559539_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$21.0</td>
<td>$20.0</td>
<td>$21.0</td>
<td>$50.00</td>
<td>$73.5K</td>
<td style="text-align: right;">43</td>
<td style="text-align: right;">39</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$32.7</td>
<td>$30.9</td>
<td>$32.52</td>
<td>$35.00</td>
<td>$65.0K</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$7.7</td>
<td>$7.6</td>
<td>$7.6</td>
<td>$65.00</td>
<td>$63.8K</td>
<td style="text-align: right;">37</td>
<td style="text-align: right;">89</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$6.1</td>
<td>$5.6</td>
<td>$5.9</td>
<td>$65.00</td>
<td>$59.0K</td>
<td style="text-align: right;">37</td>
<td style="text-align: right;">472</td>
</tr>
<tr>
<td>ALAB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$11.1</td>
<td>$10.7</td>
<td>$11.1</td>
<td>$75.00</td>
<td>$55.5K</td>
<td style="text-align: right;">425</td>
<td style="text-align: right;">66</td>
</tr>
</tbody>
</table>
</p>
<h3>About Astera Labs</h3>
<p>Astera Labs Inc is a company that offers an Intelligent Connectivity Platform, comprised of Semiconductor-based, high-speed mixed-signal connectivity products that integrate a matrix of microcontrollers and sensors. COSMOS, their software suite which is embedded in its connectivity products and integrated into their customers' systems. The Company delivers critical connectivity performance, enables flexibility and customization, and supports observability and predictive analytics. This approach addresses the data, network, and memory bottlenecks, scalability, and other infrastructure requirements of hyperscalers and system original equipment manufacturers.</p>
<p>Having examined the options trading patterns of Astera Labs, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Astera Labs</h3>
<ul>
<li>Trading volume stands at 3,996,863, with ALAB's price down by -10.18%, positioned at $63.7.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 14 days.</li>
</ul>
<h3>What Analysts Are Saying About Astera Labs</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $88.0.</p>
<ul>
<li>Reflecting concerns, an analyst from Evercore ISI Group lowers its rating to Outperform with a new price target of $100.</li>
<li>An analyst from Barclays downgraded its action to Overweight with a price target of $85. </li>
<li>Reflecting concerns, an analyst from Roth MKM lowers its rating to Buy with a new price target of $85.</li>
<li>In a cautious move, an analyst from JP Morgan downgraded its rating to Overweight, setting a price target of $85. </li>
<li>Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $85.</li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Astera Labs, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


ALAB

Decoding Astera Labs's Options Activity: What's the Big Picture?

GILD

LPTX

Leap Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 13.9% Stake In The Co As Of April 10, 2024

Vistagen Therapeutics Inc (VTGN) beat out earnings estimates for Q3 2024 this afternoon.The consensus among analysts for Vistagen Therapeutics Inc was for an earnings per share (EPS) loss of $0.30 per share. The firm was able to surpass those projections, reporting an EPS loss of $0.22 per share, a positive surprise of $0.

Vistagen Therapeutics Inc Up 5.51% To $5.17 After Earnings Beat

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The global biotechnology market is a treasure trove of <a href="https://investorplace.com/industries/healthcare/biotech/">hidden-gem biotech stocks</a>. Valued at $1.55 trillion in 2023, it is anticipated to grow at a <a href="https://tokenist.com/three-stocks-to-diversify-beyond-the-magnificent-seven-in-2024/#:~:text=The%20global%20biotechnology%20market%2C%20valued%20at%20%241.55%20trillion%20in%202023%2C%20is%20anticipated%20to%20grow%20at%20a%C2%A0CAGR%20of%2013.96%25%C2%A0from%202024%20to%202030." target="_blank">CAGR of 13.96%</a> from 2024 to 2030. Government support initiatives aiming to modernize regulatory frameworks, improve approval processes, and standardize clinical studies are key drivers. </p>



<p>The rise of personalized medicine and orphan drug formulations are expanding biotechnology applications, attracting innovative companies and boosting market revenue.</p>



<p>Growing demand for clinical solutions for chronic diseases such as cancer and diabetes propels market expansion. Major firms focus on pipeline products for Alzheimer&rsquo;s, Parkinson&rsquo;s, and cardiovascular diseases, with numerous agents in clinical trials.</p>



<p>Moreover, recent acquisitions of small drugmakers are sparking optimism among biotechnology venture capitalists. This signals potential stabilization after two years of declining investment. The surge in purchases this week builds on a busy fourth quarter for biotech mergers and acquisitions. This offers returns for venture capitalists amid a scarcity of companies going public.</p>



<p>Elsewhere, increasing demand for biotechnology tools in agriculture, including molecular breeding and genetically modified crops, fuels market growth. Tissue culture technology adoption for disease-resistant plant variants in regions like southern Asia and Africa contributes to agricultural applications.</p>



<p>Strong clinical trial pipelines and funding in tissue engineering and regenerative medicine drive market growth. Fermentation technology advancements, including simplified and vortex bioreactors, enhance operations in life sciences and healthcare. These improvements, along with wastewater processing applications, are expected to further accelerate market growth in the future.</p>



<p>Along these lines, we look at hidden-gem biotech stocks that investors should consider for 2024.</p>



<h2>Immuneering (IMRX)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600gene-300x169.jpg" alt="biotech stocks"><div>Source: Shutterstock</div></div>


<p><strong>Immuneering </strong>(NASDAQ<strong>:<a href="https://investorplace.com/stock-quotes/imrx-stock-quote/">IMRX</a>)</strong> is a small-cap biotech company focused on innovative therapies. Their dual MEKi platform offers proprietary deep cyclic inhibition (<span>DCI</span>), addressing safety and efficacy concerns in cancer treatment. There is promising preclinical data and a robust pipeline. Immuneering aims to make significant strides in oncology research and deliver novel therapies to patients in need.</p>



<p>Research firm Needham &amp; Company analyst Ami Fadia has expanded research coverage to include small-cap biotech company Immuneering. Fadia <a href="https://www.streetinsider.com/Analyst+Comments/Needham+sees+over+130%25+upside+in+this+Biotech+stock/22496535.html" target="_blank">initiated coverage</a> with a &ldquo;Buy&rdquo; rating and set a price target of $20 per share, significantly higher than the $8.44 closing price on Tuesday.&nbsp;</p>



<p>Immuneering&rsquo;s dual MEKi platform offers proprietary deep cyclic inhibition (<span>DCI)</span>, addressing safety and durability concerns of first-generation MEKi drugs while delivering higher drug concentrations. Phase 1 dose escalation of lead asset IMM-1-104 demonstrated safety, with promising preclinical data indicating efficacy in melanoma, pancreatic, and lung cancers.&nbsp;</p>



<p>The analysts estimated a total addressable market (TAM) of more than $12 billion for IMM-1-104, projecting sales of $2.5 billion in 2030 with an 11% probability of success. This hidden-gem biotech stock has surged 74% this year.</p>



<h2>Vistagen Therapeutics (VTGN)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600molecule-300x169.jpg" alt="a representation of floating molecules"><div>Source: Shutterstock</div></div>


<p><strong>Vistagen Therapeutics </strong>(NASDAQ<strong>:<a href="https://investorplace.com/stock-quotes/vtgn-stock-qu">VTGN</a>)</strong> is a biotech company with a promising future. Led by lead asset Fasedienol (PH94B), a fast-acting nasal spray for social anxiety disorder, Vistagen aims for FDA approval, potentially revolutionizing treatment for millions of affected individuals.</p>



<p>Recently, biotech analysts at Jefferies sparked notable market activity with rating changes in their research coverage, particularly raising Vistagen&rsquo;s <a href="https://seekingalpha.com/news/4044383-vistagen-shares-move-up-after-jeffries-upgrade" target="_blank">rating to &ldquo;Buy&rdquo; from &ldquo;Hold&rdquo;</a> and setting a price target of $15 per share. Shares closed at $4.90 on Friday, Feb. 9.&nbsp;</p>



<p>Analysts expressed optimism, stating that this hidden-gem biotech stock is poised for a significant turnaround as their lead asset showed positive Phase III social anxiety data. This drives confidence in FDA approval, especially since VTGN can file with just one additional positive Phase III study, with two opportunities in 2025.&nbsp;</p>



<p>If approved, PH94B could be a groundbreaking therapy for acute treatment of social anxiety disorder, a condition affecting more than 25 million adults in the United States. Tsai considers the next year pivotal for Vistagen, with significant upside potential given the estimated peak sales of $750 million, low multiple, and probability of success.&nbsp;</p>



<p>This analysis suggests a valuation exceeding $750 million, significantly higher than the current market capitalization of $200 million.</p>



<h2>Vir Biotechnology (VIR)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/02/vir-stock-1-300x169.jpg" alt="A concept image of a phone with the VIR.bio website on a smartphone"><div>Source: Karol Ciesluk / Shutterstock.com</div></div>


<p><strong>Vir Biotechnology </strong>(NASDAQ<strong>:<a href="https://investorplace.com/stock-quotes/vir-stock-quote/">VIR</a></strong>) is a biotech firm focused on developing innovative treatments for infectious diseases. With a robust pipeline and strategic partnerships, including with GlaxoSmithKline, Vir is advancing therapies to address global health challenges, such as COVID-19.&nbsp;</p>



<p>In December, Vir Biotechnology unveiled a strategic restructuring plan aimed at trimming operating expenses and channeling investments into high-potential programs, offering a glimmer of optimism to investors amid recent pipeline challenges. This beaten-down stock is down 65% over the last 52 weeks.</p>



<p>Furthermore, the company <a href="https://seekingalpha.com/news/4046214-vir-biotechnology-to-shed-12-percent-of-workforce-as-part-of-corporate-restructuring" target="_blank">initiated a significant 12% reduction in its workforce</a>. This resulted in a 75-headcount reduction, inclusive of discontinuing the innate immunity small molecule group initiated in Q3 2023. These workforce adjustments are anticipated to be largely completed by Q1 2024.</p>



<p>However, research endeavors will persist at sites in San Francisco, California and Bellinzona, Switzerland. These measures are anticipated to curtail the company&rsquo;s cost structure by a minimum of $40 million annually.&nbsp;</p>



<p>Despite these adjustments, Vir Biotechnology concluded Q3 with a robust $1.7 billion in cash, cash equivalents, and investments. Vir Biotechnology announced an expansion of its strategic focus towards autoimmune diseases and immuno-oncology.&nbsp;</p>



<p>Moreover, the company is poised to unveil clinical data from its phase II study on Tobevibart (VIR-3434) and Elebsiran (VIR-2218). These are for treating chronic hepatitis delta in Q2 2024. This could serve as a catalyst for this hidden-gem biotech stock.</p>



<p><em>On the date of publication, Shane Neagle did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://protect-us.mimecast.com/s/XtC3C1wq33iErOvYSGOsXg?domain=investorplace.com/">Publishing Guidelines</a>.</em></p>
<div><p>Shane Neagle is fascinated by the ways in which technology is poised to disrupt investing. He specializes in fundamental analysis and growth investing.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/02/3-hidden-gem-biotech-stocks-se-to-ride-a-massive-market-wave/">3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on VistaGen Therapeutics (VTGN – Research Report). The associated price targ...

Buy Rating Affirmed for VistaGen: Promising Clinical Results and Strong Financial Outlook

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Investing in high-potential <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> should catapult your portfolio to new heights. Picture this: a global biotech market valued at a whopping $1.55 trillion in 2023 is set to catapult to <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">$3.08 trillion by 2030</a>, with a compound annual growth rate of 14%. Beyond the numbers, the competitive fervor among biotechs adds an intriguing layer to this dynamic sector. In the face of such exponential growth, savvy investors have a unique opportunity to ride the wave of innovation and financial prosperity ahead.</p>



<p>Success for biotech businesses hinges on meticulous research, vigilantly overseen by the U.S. Food and Drug Administration. Within this dynamic arena, three remarkable <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> surface as compelling opportunities. They allow investors to contribute to medical progress and pave a pathway to substantial financial returns.</p>



<h2>Ardelyx (ARDX)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>


<p><strong>Ardelyx</strong> (NASDAQ:<strong><a href="https://investorplace.com/stock-quotes/ardx-stock-quote/">ARDX</a></strong>) has captivated the biotech sector, showcasing <a href="https://seekingalpha.com/symbol/ARDX/momentum/performance">an 182.2% surge</a> in share price over the past year, propelled by innovative oral medications. The company heralded 2023 as a transformative year, transitioning to a commercial entity, with IBSRELA&rsquo;s third-quarter net sales <a href="https://seekingalpha.com/pr/19515897-ardelyx-reports-third-quarter-2023-financial-results-and-updates-2023-u-s-ibsrela-net-sales">reaching $22.3 million.</a> Moreover, the <a href="https://seekingalpha.com/news/4026821-ardelyx-gaap-eps-of-0_03-beats-0_14-revenue-of-56_4m-beats-33_83m">revenue skyrocketed to $56.4 million</a>, boasting a phenomenal 1030.3% year-over-year (YOY) surge, surpassing projections by an impressive $33.83 million.</p>



<p>Building on the triumph of IBSRELA, Ardelyx achieves another milestone with the FDA&rsquo;s approval of XPHOZAH for chronic kidney disease patients on dialysis. The approval stands as a testament to Ardelyx&rsquo;s strategic prowess and commitment to advancing medical treatment, marking another major achievement in the company&rsquo;s trajectory.</p>



<p>Furthermore, Ardelyx is making marked advancements, as evidenced by consistent quarter-over-quarter growth. With a robust financial position, including <a href="https://seekingalpha.com/pr/19515897-ardelyx-reports-third-quarter-2023-financial-results-and-updates-2023-u-s-ibsrela-net-sales">$165.1 million in cash and investments</a>, the company is primed for further innovation and impact in the biopharma space.</p>



<h2>Vertex Pharmaceuticals (VRTX)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/06/vrtx-stock-1-300x169.jpg" alt="Vertex Pharmaceuticals (VRTX) logo visible on display screen"><div>Source: Pavel Kapysh / Shutterstock.com</div></div>


<p><strong>Vertex Pharmaceuticals</strong> (<strong>NASDAQ</strong>:<strong><a href="https://investorplace.com/stock-quotes/vrtx-stock-quote/">VRTX</a></strong>) has spread its tentacles beyond its popular cystic fibrosis treatments to leap into gene therapy for sickle cell disease. The <a href="https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-casgevytm-exagamglogene">recent FDA approval of Casgevy</a> for sickle cell disease has also been given a green light by the European Commission. This dual approval underscores Vertex&rsquo;s strategic prowess and commitment to addressing critical genetic disorders.</p>



<p>Meanwhile, the company&rsquo;s valuation is on an upward trajectory, with the <a href="https://seekingalpha.com/symbol/VRTX/momentum/performance">stock climbing over 38%</a> in the past year. Vertex&rsquo;s dazzling <a href="https://seekingalpha.com/symbol/VERX/growth">16.2% YOY revenue growth</a> compared to the sector median of a mere 4.7% further cements its position as a biotech juggernaut. This remarkable journey is underpinned by a stellar <a href="https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/gross-profit">100% gross profit margin</a> compared to the sector median of just 57.1%, showcasing robust financial health.</p>



<p>As Vertex expands its horizon, it stands on the brink of a valuation renaissance, promising an exhilarating future for investors interested in biotech stocks.</p>



<h2>Vistagen Therapeutics (VTGN)</h2>


<div>
<a href="https://investorplace.com/wp-content/uploads/2024/02/vtgn-vistagen.png"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/vtgn-vistagen-300x169.png" alt=""></a></div>


<p><strong>VistaGen Therapeutics</strong> (NASDAQ: <strong><a href="https://investorplace.com/stock-quotes/vtgn-stock-qu/">VTGN</a></strong>) has captured the spotlight in its niche, generating significant waves with its Fasedienol (PH94B) nasal spray. Successfully navigating its <a href="https://www.prnewswire.com/apac/news-releases/affamed-therapeutics-announces-partner-vistagen-reports-positive-top-line-results-from-phase-3-palisade-2-trial-of-fasedienol-ph94b-nasal-spray-in-social-anxiety-disorder-301897688.html">Phase 3 trial</a>, this nasal spray emerges as a potential game-changer for social anxiety disorder. It is poised to pave the way for a groundbreaking FDA-approved treatment.</p>



<p>Financially robust, VistaGen&rsquo;s astounding <a href="https://seekingalpha.com/symbol/VTGN/momentum/performance">24% year-to-date stock surge</a> underscores its resilience and market appeal. With its <a href="https://seekingalpha.com/news/4066406-vistagen-therapeutics-gaap-eps-of-0_22-beats-0_08-revenue-of-0_41m-misses-0_13m">third-quarter GAAP</a> earnings per share of negative 22 cents, surpassing expectations by eight cents. Simultaneously, the revenue surged to $0.41 million, marking an 127.8% YOY increase, the positive momentum is undeniably promising.</p>



<p>Furthermore, &lsquo;<a href="https://www.tipranks.com/stocks/vtgn/forecast">TipRanks</a>&lsquo; analysts project an impressive 179% upside potential, affirming unwavering confidence in VistaGen&rsquo;s positive trajectory. Looking ahead, revenue forecasts suggest a <a href="https://finance.yahoo.com/news/vistagen-therapeutics-third-quarter-2024-104735512.html">69% annual growth</a> over the next three years, far outstripping the Biotech industry&rsquo;s anticipated 17% growth in the U.S. This stark contrast underscores VistaGen&rsquo;s standout position, solidifying its role not just as a participant but as a frontrunner in the biotech sphere.</p>



<p><em>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a></em></p>
<div><p>Muslim Farooque is a keen investor and an optimist at heart. A life-long gamer and tech enthusiast, he has a particular affinity for analyzing technology stocks. Muslim holds a bachelor&rsquo;s of science degree in applied accounting from Oxford Brookes University.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/02/3-revolutionary-biotech-stocks-poised-for-10x-surge/">3 Revolutionary Biotech Stocks Poised for 10X Surge</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Revolutionary Biotech Stocks Poised for 10X Surge

Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments

Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish

Vistagen Therapeutics Inc (VTGN) stock is higher by 25.83% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. Vistagen Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on VTGN!See Full VTGN ReportWhat is Stock Sentiment

Is Vistagen Therapeutics Inc (VTGN) a Stock to Watch After Gaining 25.83% This Week?

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Finding undiscovered opportunities can result in significant profits in an investment landscape frequently controlled by well-known giants. These three obscure stocks have the potential to provide impressive profits. These businesses fall into three industries: healthcare, consumer staples, and information technology. Each company holds unique opportunities for development and tactical benefits.</p>



<p>The first one, in the technology distribution industry, is notable for having an excellent inventory control system and a strong balance sheet. The company has reduced excess inventory levels, and effective inventory turnover rates promote this. </p>



<p>The second one competes in the food retail sector. The company has seen an increase in digital sales and loyalty program members. Strategic investments in digital infrastructure may propel revenue growth for the organization.</p>



<p>Lastly, the third one, a biotechnology company, has a wide range of products in development intended to treat neurological conditions. These include major depressive disorders and conditions related to women&rsquo;s health. The company is preparing for its primary clinical-stage program&rsquo;s Phase 2B trials. </p>



<h2>ScanSource (SCSC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/data-automation-cloud-marketing-300x169.png" alt="An image of a robot reaching toward a laptop, surrounded by chat bubbles and graphs"><div>Source: klyaksun/Shutterstock</div></div><p>As of Q2 fiscal 2024, <strong>ScanSource</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/scsc-stock-quote/"><strong>SCSC</strong></a></span>) had a net debt leverage ratio of&nbsp;<a href="https://www.scansource.com/~/media/Project/scansource/scansourceweb/scansource-corp/investors/earnings/SCSC-Exhibit-991-12312023.pdf" target="_blank">around 0.8 times</a>&nbsp;trailing 12-month adjusted EBITDA. This demonstrates the company&rsquo;s continued strength on its financial sheet. In addition, the company&rsquo;s current credit arrangement has enough cash to meet its strategic goals.&nbsp;</p>



<p>Additionally, inventory turns show how frequently a business sells out and replaces its stock over a certain time frame. In Q2, ScanSource turned inventory over 5.1 times, the quickest in the previous five quarters. This suggests effective inventory control and a decrease in surplus inventory levels. This might result in capital lockups and higher carrying costs.</p>



<p>Furthermore, ScanSource&rsquo;s Days Sales Outstanding (DSO) dropped to&nbsp;<a target="_blank" href="https://seekingalpha.com/article/4667955-scansource-inc-scsc-q2-2024-earnings-call-transcript">68 days in Q2</a>, the lowest level in the previous five quarters. A shorter DSO indicates better liquidity and quicker cash conversion, enabling the company to reinvest money more effectively.&nbsp;</p>



<p>Finally, ScanSource Intelisys&rsquo; net billings rose to almost&nbsp;<a href="https://seekingalpha.com/article/4667955-scansource-inc-scsc-q2-2024-earnings-call-transcript" target="_blank">$2.64 billion&nbsp;</a>annually. Meanwhile, the company&rsquo;s net sales for the second quarter rose 7.5% year-over-year (YoY). Hence, this expansion drove strong demand for services like Unified Communications as a Service (UCaaS) and Contact Center as a Service (CCaaS).</p>



<h2>Albertsons (ACI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/shutterstock_2146418893-300x169.jpg" alt="ACI stock: the Albertsons logo on the side of a building."><div>Source: Tada Images / Shutterstock</div></div><p><strong>Albertsons</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/aci-stock-quote/"><strong>ACI</strong></a></span>) reached 38.5 million loyalty program members in Q3 2023, a&nbsp;<a href="https://www.albertsonscompanies.com/newsroom/press-releases/news-details/2024/Albertsons-Companies-Inc.-Reports-Third-Quarter-Fiscal-2023-Results/default.aspx" target="_blank">17% YoY gain</a>. The company sharply applied a loyalty program as a primary marketing tactic to keep consumers through customized rewards based on specific preferences and purchase patterns. Albertsons has progressively engaged customers through its loyalty program offers and fostered long-term connections. This can be seen in the solid rise in program participants.</p>



<p>In addition, digital sales at Albertsons increased significantly compared to Q3 2022, expanding at a pace of 21%. <a href="https://www.albertsonscompanies.com/newsroom/press-releases/news-details/2024/Albertsons-Companies-Inc.-Reports-Third-Quarter-Fiscal-2023-Results/default.aspx">Albertsons&rsquo; 21% rise</a> in digital sales demonstrates its fundamental capacity to capitalize on the expanding trend of online shopping and adjust to changing consumer preferences. Fundamentally, Albertsons&rsquo; investments in digital infrastructure, technology, and omnichannel capabilities derived a sharp boost in digital sales.</p>



<p>Overall, Albertsons has made it accessible for customers to buy groceries remotely. The company provides convenient online ordering, delivery and curbside pickup options. This has mainly emerged during the COVID-19 epidemic. </p>



<h2>Vistagen (VTGN)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/02/vtgn-vistagen.png"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/vtgn-vistagen-300x169.png" alt="The logo for VistaGen Therapeutics, Inc (VTGN) is seen on a white background."></a><p><strong>Vistagen</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/vtgn-stock-quote/"><strong>VTGN</strong></a></span>) has a variety of clinical-stage neuroscience assets in the pipeline. These include fasedienol, itruvone for major depressive disorder (MDD), and hormone-free&nbsp;<a href="https://seekingalpha.com/article/4669939-vistagen-therapeutics-inc-vtgn-q3-2024-earnings-call-transcript" target="_blank">PH80 for women&rsquo;s health purposes</a>. Thanks to this varied pipeline, the company may target several therapeutic areas with major unmet medical needs, including women&rsquo;s health, anxiety and depression.</p>



<p>Furthermore, Vistagen&rsquo;s pipeline&rsquo;s breadth indicates its strategic focus on treating various neurological and psychiatric illnesses. The company is utilizing cutting-edge neuroscience techniques to provide ground-breaking treatments. Vistagen augments its prospects for commercial triumph and sustained expansion by pursuing several indications with significant market potential.</p>



<p>Apart from progressing its primary clinical program, Vistagen is assiduously gearing up for prospective&nbsp;<a target="_blank" href="https://seekingalpha.com/article/4669939-vistagen-therapeutics-inc-vtgn-q3-2024-earnings-call-transcript">Phase 2B itruvone</a>&nbsp;studies in major depressive disorder (MDD). The company focuses on pushing its pipeline assets through the clinical development stages.&nbsp;</p>



<p>The <a href="https://www.vistagen.com/news-releases/news-release-details/vistagen-reports-fiscal-2024-third-quarter-financial-results-and" target="_blank">start of Phase 2B</a>&nbsp;studies is a significant turning point in the evolution of itruvone as a distinct treatment for MDD. Lastly, Vistagen has demonstrated its dedication to broadening its medication portfolio and targeting a broader spectrum of mental illnesses by extending its clinical development activities beyond fasedienol.</p>



<p><em>On the date of publication, Yiannis Zourmpanos did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.</em></p>
<div><p>Yiannis Zourmpanos is the founder of Yiazou Capital Research, a stock-market research platform designed to elevate the due diligence process through in-depth business analysis.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/03/secret-superstars-3-unknown-stocks-to-turn-5k-into-100k-by-2027/">Secret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Secret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Finding possibilities in investing frequently depends on finding companies attached to rapid expansion and value generation. Examine these three prospects, each selling at less than $10 per share and expected to see significant returns by 2027.</p>



<p>With a significant growth in overall revenue in 2023, the first one stands out for its strategic pivot towards Software as a Service revenue. This change aligns the business with consumer preferences for subscription-based business models.</p>



<p>Similarly, the second one shows strong growth in domestic sales, as demonstrated by an astounding 9% gain in Q4 2023. Likewise, the company&rsquo;s domestic expansion strategy has paid off, driving total revenue growth.</p>



<p>The third uses clinical-stage resources to address important gaps in treating neuropsychiatric illnesses. This can be seen in the encouraging Phase 3 findings for social anxiety disorder and ongoing research projects for other indications.</p>



<p>Learn how these prospects are similar in that they are strategically positioned within their respective industries and take an innovative approach.</p>



<h2>PowerFleet (PWFL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/supply-chain-shipping-logistics-1600-300x169.png" alt="logistics stocks. supply chain stocks"><div>Source: Travel mania / Shutterstock.com</div></div><p>The shift in <strong>PowerFleet&rsquo;s</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/pwfl-stock-quote/"><strong>PWFL</strong></a></span>) revenue mix toward higher-quality SaaS revenue is shown in the increase in service revenue. This component of revenue increased from 58% in 2022 to&nbsp;<a href="https://d1io3yog0oux5.cloudfront.net/_ae9ef5adfadbea5340cca51a1d8c6e14/powerfleet/news/2024-03-12_Powerfleet_Reports_Full_Year_2023_and_Fourth_447.pdf" target="_blank">63% in 2023</a>. It offers a more consistent income stream and aligns with market trends that support subscription-based revenue models.</p>



<p>In 2023, PowerFleet started a&nbsp;<a href="https://finance.yahoo.com/news/powerfleet-inc-nasdaq-pwfl-q4-124126816.html" target="_blank">major transformation plan</a> to change its revenue structure, improve its technology, and reach a wider audience. Similarly, the company&rsquo;s adaptability and dedication to maintaining its competitiveness in the market are evident in its proactive strategy.</p>



<p>Moreover, a hallmark of PowerFleet&rsquo;s strategic growth initiatives is the upcoming merger with MiX Telematics and the purchase of Movingdots in Q1 2023. The&nbsp;anticipated gains&nbsp;in trailing 12-month revenue and EBITDA post-merger demonstrate that these acquisitions strengthen the company&rsquo;s technological skills and market presence.</p>



<p>To sum up, PowerFleet&rsquo;s capacity to obtain funding for debt restructuring and acquisitions demonstrates the company&rsquo;s strength and stability. Completing the loan agreements with Bank Hapoalim and Rand Merchant Bank highlights the company&rsquo;s capital availability and fortifies its balance sheet. As a result, this offers a solid basis for further expansion plans.</p>



<h2>CompoSecure (CMPO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/01/creditcards1600-300x169.jpg" alt="a pile of credit cards, credit card interest rates"><div>Source: Teerasak Ladnongkhun/Shutterstock.com</div></div><p>One noteworthy tendency for <strong>CompoSecure</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/cmpo-stock-quote/"><strong>CMPO</strong></a></span>) is the outperformance of net sales in the country instead of outside sales. The business highlighted the strength of its US market operations in Q4 2023 by reporting a&nbsp;<a href="https://ir.composecure.com/news-releases/news-release-details/composecure-reports-fourth-quarter-and-full-year-2023-financial" target="_blank">9% rise in domestic net sales</a>. This pattern aligns with the full-year results, indicating that the total rise in net sales was driven mainly by sustained domestic growth. </p>



<p>Additionally, due to the world economy&rsquo;s unpredictability, CompoSecure&rsquo;s concentration on local expansion has paid off. This propels total revenue growth even while overseas sales fluctuate somewhat.</p>



<p>Meanwhile, continuing&nbsp;<a href="https://finance.yahoo.com/news/composecure-inc-nasdaq-cmpo-q4-160013352.html" target="_blank">long-term contracts</a>&nbsp;with prestigious customers like <strong>American</strong> <strong>Express</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/axp-stock-quote/"><strong>AXP</strong></a></span>) and <strong>JP</strong> <strong>Morgan</strong> <strong>Chase</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/jpm-stock-quote/"><strong>JPM</strong></a></span>) contributes to CompoSecure&rsquo;s optimism over revenue growth. These contracts offer a steady flow of income and reinforce the business&rsquo;s standing as a reliable partner for significant financial institutions. Thus, CompoSecure guarantees a steady income stream by establishing long-term contracts with important clients.&nbsp;</p>



<p>In short, thanks to careful operational expenditure management, CompoSecure saw a stunning <a href="https://ir.composecure.com/news-releases/news-release-details/composecure-reports-fourth-quarter-and-full-year-2023-financial" target="_blank">39% annual rise in net income</a>&nbsp;for Q4 2023. Therefore, the profitability partly increased because selling, general, and administrative costs were reduced.</p>



<h2>Vistagen (VTGN)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/02/vtgn-vistagen.png"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/vtgn-vistagen-300x169.png" alt="The logo for VistaGen Therapeutics, Inc (VTGN) is seen on a white background."></a><p>Clinical-stage assets in <strong>Vistagen&rsquo;s</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/vtgn-stock-quote/"><strong>VTGN</strong></a></span>) pipeline address vital demand in neuropsychiatric diseases. These include major depressive disorder, SAD, and indications related to women&rsquo;s health. There are continued preparations for the&nbsp;<a href="https://finance.yahoo.com/news/vistagen-therapeutics-inc-nasdaq-vtgn-132008646.html" target="_blank">PALISADE Phase 3</a>&nbsp;development program. With that, the company&rsquo;s primary program, fasedienol, has shown encouraging Phase 3 findings for SAD. </p>



<p>Additionally, Vistagen is aggressively using encouraging trial results and market prospects to advance its pipeline initiatives. This includes&nbsp;itruvone&nbsp;for MDD and rapid-onset hormone-free (PHAD) nasal spray for women&rsquo;s health.</p>



<p>Indeed, developing a focused pipeline in therapeutic areas enhances the company&rsquo;s growth potential. These areas are in high demand since they coincide with market trends and unmet medical demand. Thus, clinical initiatives moving closer to the phases of regulatory clearance represent expanded revenue streams and higher valuations.&nbsp;</p>



<p>In Q3 fiscal 2024, Vistagen&rsquo;s net loss dropped to&nbsp;<a target="_blank" href="https://www.vistagen.com/news-releases/news-release-details/vistagen-reports-fiscal-2024-third-quarter-financial-results-and">$6.3 million</a>&nbsp;from $9.8 million in Q3 2023. A decrease in net loss indicates that financial sustainability is getting closer. As of 2023, Vistagen had around $126.6 million in cash. Overall, the company&rsquo;s significant cash reserves improve its capacity to handle market volatility and lessen its reliance on outside funding.</p>



<p><em><em>On the date of publication, Yiannis Zourmpanos did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.</em><a href="https://investorplace.com/stock-quotes/-stock-quote/"></a></em></p>
<div><p>Yiannis Zourmpanos is the founder of Yiazou Capital Research, a stock-market research platform designed to elevate the due diligence process through in-depth business analysis.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/04/millionaire-makers-3-stocks-under-10-set-to-skyrocket-by-2027/">Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>If you&rsquo;re searching for stocks under $15, look no further. These seven offerings, all priced below $15, present a unique opportunity for individual investors to profit from future development. These equities cover various industries, from cutting-edge science and financial services to booming energy production and development opportunities, offering a diverse portfolio for potential profit.</p>



<p>The first one achieved an increasing market reach and improved financial stability through a deliberate change towards income diversification. Similarly, the latter can continue to profit even in the face of inflation. These stocks are resilient to market fluctuations, providing a secure investment option. Potential advances in the field of healthcare are indicated by the third one&rsquo;s progress in clinical trials for the treatment of depression and social anxiety.</p>



<p>In the meantime, the fourth technology company&rsquo;s success with connected TV (<span>CTV</span>) advertising highlights its capacity to adjust to changing market conditions. Additionally, the fifth one shows a dedication to sustainable expansion by optimizing operational performance.</p>



<p>Next, the sixth one&rsquo;s steadily increasing earnings from royalties and flagship items highlight its place in the market and steadiness. Finally, the energy sector&rsquo;s solid production increase in the seventh demonstrates how well it can access profitable hydrocarbon sources.</p>



<h2>Stocks Under $15: SoFi (SOFI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/03/sofi1600-3-300x169.png" alt="SoFi logo sign on headquarters facade. Social Finance is an online personal finance company."><div>Source: Michael Vi / Shutterstock.com</div></div><p>By effectively diversifying its top-line, <strong>SoFi</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/sofi-stock-quote/"><strong>SOFI</strong></a></span>) has increased its target market and decreased its need in the lending segment. Thus, non-lending sectors increased their share of adjusted net revenue from&nbsp;<a href="https://s27.q4cdn.com/749715820/files/doc_financials/2023/q4/SoFi-Q4-2023-Earnings-Release.pdf" target="_blank">34% to 40%</a>&nbsp;in Q4 2023. </p>



<p>Additionally, the Financial Services division had exceptional growth, with net sales rising to $139.1 million, an increase of 115% over the previous year. In addition, the technology platform business showed consistent growth, as seen by a<a href="https://s27.q4cdn.com/749715820/files/doc_financials/2023/q4/SoFi-Q4-2023-Earnings-Release.pdf" target="_blank">&nbsp;13% boost in net sales</a>&nbsp;over the prior year. These developments indicate SoFi&rsquo;s capacity to seize chances outside of the conventional loan space and use its platforms for financial services and technology to boost income.</p>



<p>Moreover, by reducing SoFi&rsquo;s exposure to the risks associated with any one product or market, income stream diversification improves the company&rsquo;s consolidated financial stability and resilience. Hence, by going beyond loans, SoFi will be able to reach a broader spectrum of consumer demands and enter new market sectors, opening up new growth prospects. </p>



<h2>CompoSecure (CMPO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/01/creditcards1600-300x169.jpg" alt="a pile of credit cards, credit card interest rates"><div>Source: Teerasak Ladnongkhun/Shutterstock.com</div></div><p><strong>CompoSecure</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/cmpo-stock-quote/"><strong>CMPO</strong></a></span>) has reported a pattern of increasing bottom-line. This reflects net income and adjusted EBITDA boosts attained under obstacles such as fluctuations in fair value obligations and inflationary pressure. Comparing Q4 2023 against Q4 2022, net income<a href="https://ir.composecure.com/news-releases/news-release-details/composecure-reports-fourth-quarter-and-full-year-2023-financial" target="_blank">&nbsp;increased by 39%</a>.&nbsp;</p>



<p>Indeed, reductions in expenditures, with other conservative operational expense management, led to this gain in the bottom line. Net income was also positively impacted by adjustments to the earnout consideration liability, derivative liability, and warrant liabilities&rsquo; fair values. Similarly, adjusted EBITDA&nbsp;<a href="https://ir.composecure.com/news-releases/news-release-details/composecure-reports-fourth-quarter-and-full-year-2023-financial" target="_blank">increased considerably</a>&nbsp;over the year. The company has focused on increasing its operational edge and boosting its bottom line. This is observed in the increase generated by net sales growth and operating expenditure reductions.</p>



<p>Overall, CompoSecure showed its adaptability and success in challenging market conditions by boosting adjusted EBITDA despite obstacles like&nbsp;<a target="_blank" href="https://finance.yahoo.com/news/composecure-inc-nasdaq-cmpo-q4-160013352.html">inflationary pressure</a>.</p>



<h2>Stocks Under $15: Vistagen (VTGN)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/02/vtgn-vistagen.png"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/vtgn-vistagen-300x169.png" alt="The logo for VistaGen Therapeutics, Inc (VTGN) is seen on a white background."></a><p>One of the main factors influencing <strong>Vistagen&rsquo;s</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/vtgn-stock-quote/"><strong>VTGN</strong></a></span>) growth potential is the <a href="https://www.vistagen.com/news-releases/news-release-details/vistagen-reports-fiscal-2024-third-quarter-financial-results-and" target="_blank">PALISADE Phase 3 program</a>. This focuses on developing fasedienol specifically for the acute treatment of social anxiety disorder (SAD). The PALISADE-3 trial may begin in H1 2024, and the PALISADE-4 trial may begin in H2 2024. These schedules show essential turning points in the organization&rsquo;s clinical development process.</p>



<p>Furthermore, the purpose of the multicenter, randomized, double-blind, placebo-controlled PALISADE studies is to assess the safety, tolerability, and&nbsp;<a href="https://finance.yahoo.com/news/vistagen-therapeutics-inc-nasdaq-vtgn-132008646.html" target="_blank">effectiveness of fasedienol</a>&nbsp;in adult patients with SAD. The trials are conducted in the United States and use the Subjective Units of Distress Scale (SUDS) as the primary efficacy objective to evaluate how well fasedienol relieves anxiety symptoms following a single dosage during a public speaking challenge.</p>



<p>Apart from fasedienol, Vistagen is also promoting the development of itruvone for the treatment of major depressive disorder (MDD) and PH80 for indications related to women&rsquo;s health. Planning and preparations are in place for Itruvone&rsquo;s&nbsp;<a href="https://www.vistagen.com/static-files/b1bcf087-576a-4e58-bd6c-4f5cdd9ad907" target="_blank">Phase 2B development for MDD</a>. In short, this suggests that Vistagen is strategically expanding its pipeline to target depression.</p>



<h2>Viant (DSP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/03/digital-advertising-1600-300x169.jpg" alt="Close up hand holding mobile with Digital Advertising and icons, Digital Marketing concept. digital ad stocks"><div>Source: weedezign via Shutterstock</div></div><p><strong>Viant</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/dsp-stock-quote/"><strong>DSP</strong></a></span>) has cutting-edge technological solutions and tactical efforts like Direct Access. This has proven to be a formidable force in the CTV advertising market. CTV is the company&rsquo;s biggest channel. In the fourth quarter of 2023, it accounted for about&nbsp;<a href="https://investors.viantinc.com/news-releases/news-release-details/viant-technology-announces-fourth-quarter-and-full-year-2023" target="_blank">40% of all ad expenditures</a>&nbsp;on Viant&rsquo;s platform. Viant&rsquo;s Household ID technology addresses the issues raised by the deprecation of cookies. This allows targeted advertising in cookie-free contexts, which is a major factor in this boost in ad expenditures.</p>



<p>Moreover, Viant&rsquo;s clientele and spending volumes have increased considerably, especially with larger mid-market clients. The number of clients making above $1 million in contributions in 2023 <a href="https://investors.viantinc.com/news-releases/news-release-details/viant-technology-announces-fourth-quarter-and-full-year-2023" target="_blank">rose by over 20%</a>&nbsp;compared to 2022. Furthermore, there were more than&nbsp;<a href="https://investors.viantinc.com/static-files/f8229159-9a45-44af-a22a-d0d7c81cf0e2" target="_blank">30% more clients</a>&nbsp;with over $500K in contributions than there were a year before.</p>



<p>To sum up, these patterns suggest Viant&rsquo;s ability to draw in and cater to larger clients with considerable advertising expenditures. Viant has increased its market reach and strengthened its ties with important clients by concentrating on the mid-market area and providing customized solutions that satisfy their demands.</p>



<h2>Stocks Under $15: SNDL (SNDL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/sndl-1600-300x169.png" alt="The Sundial Growers logo is on a phone screen with a light blue background in front of the sundial logo on a white background. SNDL stock"><div>Source: Shutterstock</div></div><p>In 2023, with an operating loss of&nbsp;<a href="https://s201.q4cdn.com/372870431/files/doc_news/SNDL-Reports-Full-Year-and-Fourth-Quarter-2023-Financial-and-Operational-Results-2024.pdf" target="_blank">$162.8 million,&nbsp;</a><strong>SNDL</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/sndl-stock-quote/"><strong>SNDL</strong></a></span>) marked a considerable uplift in operating performance. This loss was based on (partially) restructuring and goodwill impairment. However, it is<a href="https://s201.q4cdn.com/372870431/files/doc_earnings/2023/q4/presentation/SNDL-Q4-2023-Corporate-Presentation.pdf" target="_blank">&nbsp;up 53% from 2022&rsquo;s loss</a>&nbsp;of $347.8 million, which signifies a solid move towards a complete turnaround. Likewise, in Q4 2023, the operating loss was $84.9 million. Again, this is a 45% improvement from Q4 2022 ($154.6 million loss).</p>



<p>Similarly, in 2023, adjusted EBITDA from continuing operations was&nbsp;<a href="https://s201.q4cdn.com/372870431/files/doc_earnings/2023/q4/transcript/final-sndl-inc-q4-2023-results.pdf" target="_blank">$29.2 million</a>. This is a solid increase over 2022&rsquo;s deficit of $15.8 million. Furthermore, adjusted EBITDA from continuing operations improved drastically by 147% to $3.5 million in Q4 2023 from Q4 2022.</p>



<p>Fundamentally, these gains in operational performance suggest SNDL&rsquo;s focus on margin expansion, cost reduction, and operational edge. Overall, by improving its operating performance, SNDL can achieve sustainable growth, optimize its bottom line, and build long-term value.</p>



<h2>Puma Biotechnology (PBYI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/cancer-300x169.jpg" alt="A variety of pills, pill bottles, and droppers arranged on a table in multiple bright colors."><div>Source: Shutterstock</div></div><p><strong>Puma Biotechnology</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/pbyi-stock-quote/"><strong>PBYI</strong></a></span>) has constantly increased, with slight product and net&nbsp;revenue swings. This includes revenue from sales of NERLYNX. Similarly, product revenue for 2023 was $203.1 million, stable annually. The annual comparison shows a slight growth in product revenue. </p>



<p>Indeed, this expansion suggests that there is still a market lead for Puma Biotechnology&rsquo;s <a href="https://s24.q4cdn.com/201644000/files/doc_earnings/2023/q4/presentation/Puma-Q4-23-Commercial-Slides-Final.pdf" target="_blank">main product, NERLYNX</a>, which is crucial to the company&rsquo;s total earnings. Moreover, Puma Biotechnology derives top-line from royalties in addition to product sales. This adds to the stability of its consolidated revenue. Royalty revenue for&nbsp;<a href="https://finance.yahoo.com/news/puma-biotechnology-inc-nasdaq-pbyi-132935557.html" target="_blank">2023 was $32.5 million</a>, uplifted from $28.0 million in 2022. </p>



<p>To conclude, Puma Biotechnology&rsquo;s top-line solidity is intensified by the stability of royalty revenue, balancing with the boost in product sales.</p>



<h2>Granite Ridge (GRNT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/03/oilandgasstocks1600-300x169.png" alt="Panorama of Oil and Gas central processing platform in twilight, offshore hard work occupation twenty four working hours. Best oil stocks to buy"><div>Source: Oil and Gas Photographer / Shutterstock.com</div></div><p>Solid performance during Q4 and 2023 indicates <strong>Granite Ridge&rsquo;s</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/grnt-stock-quote/"><strong>GRNT</strong></a></span>) high boost in output. Compared to Q4 2022, <a href="https://s202.q4cdn.com/863234614/files/doc_financials/2023/q4/Granite-Ridge-Resources-Inc-Reports-Fourth-Quarter-and-Full-Year-2023-Results-and-Provides-Outlook-for-2024-2024.pdf" target="_blank">production increased by 18%&nbsp;</a>to over 26K barrels of oil equivalent (Boe) per day. In particular, oil output rose 8% to 12.28K barrels per day. Natural gas output increased by 29% to over 82.5K thousand cubic feet (Mcf) per day.</p>



<p>In 2023, total production boosted by&nbsp;<a target="_blank" href="https://s202.q4cdn.com/863234614/files/doc_financials/2023/q4/Granite-Ridge-Resources-Inc-Reports-Fourth-Quarter-and-Full-Year-2023-Results-and-Provides-Outlook-for-2024-2024.pdf">23% to 24,311 Boe</a>&nbsp;per day compared to 2022. Oil production increased by 14% to 11.4K barrels. Natural gas output increased considerably by&nbsp;<a target="_blank" href="https://finance.yahoo.com/news/granite-ridge-resources-inc-nyse-123352999.html">32% to 77.4K</a>&nbsp;Mcf per day. Granite Ridge&rsquo;s exploration and extraction efforts have proven effective, as seen in a solid and rapid boost in output.&nbsp;</p>



<p>To sum up, these patterns show that the business may effectively access hydrocarbon reserves, which translates into a higher prospective income stream. Therefore, Granite Ridge&rsquo;s solid production increase puts it in a good position for future development and competitiveness in the market.</p>



<p><em>As of this writing, Yiannis Zourmpanos held a long position in SOFI. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.</em></p>
<div><p>Yiannis Zourmpanos is the founder of Yiazou Capital Research, a stock-market research platform designed to elevate the due diligence process through in-depth business analysis.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/04/7-stocks-under-15-predicted-to-boom-in-the-next-2-years/">7 Stocks Under $15 Predicted to Boom in the Next 2 Years</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Stocks Under $15 Predicted to Boom in the Next 2 Years

ARDX

CMPO

GRNT

IMRX

PBYI

PWFL

SCSC

SNDL

SOFI

VRTX

Press Releases

Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results

Major Depressive Disorder Market: Latest Study by DelveInsight Forecasts Remarkable Growth During the Forecast Period (2023-32) | AbbVie, BioLite, Bristol-Myers Squibb, GH Research, Janssen, Novartis

Opinion

Thinking about trading options or stock in Adobe, Taiwan Semiconductor, AerSale Corp, Vistagen Therapeutics, or Chewy Inc?

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024

Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update

Vistagen to Present at TD Cowen 44th Annual Health Care Conference

Vistagen to Present at Stifel 2024 Virtual CNS Days

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference